Publicaciones en las que colabora con Eva Pérez Pampín (12)

2017

  1. Diagnostic Value and Validity of Early Spondyloarthritis Features: Results From a National Spanish Cohort

    Arthritis Care and Research, Vol. 69, Núm. 6, pp. 938-942

  2. Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial Spondyloarthritis

    Arthritis Care and Research, Vol. 69, Núm. 1, pp. 150-155

2016

  1. Centre-related variability in hospital admissions of patients with spondyloarthritis

    Rheumatology International, Vol. 36, Núm. 9, pp. 1301-1308

  2. Differences between familial and sporadic early spondyloarthritis: Results from the ESPERANZA cohort

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 4, pp. 575-580

2014

  1. Observational study of optimization of biologic therapies in rheumatoid arthritis: A single-centre experience

    Rheumatology International, Vol. 34, Núm. 8, pp. 1059-1063

2013

  1. Le facteur rhumatoïde ne semble pas prédire la réponse aux anti-TNF α dans la polyarthrite rhumatoïde: expérience de trois centres

    Revue du Rhumatisme (Edition Francaise)

  2. Orthopedic surgery in rheumatoid arthritis in the era of biologic therapy

    Journal of Rheumatology, Vol. 40, Núm. 11, pp. 1850-1855

  3. Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: Three centers experience

    Joint Bone Spine

2011

  1. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0

    Rheumatology, Vol. 50, Núm. 1, pp. 85-92

2010

  1. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 10, pp. 1751-1755

2008

  1. Reacciones adversas relacionadas con la administración de inhibidores del TNF. Análisis de un registro de terapias biológicas

    Reumatologia Clinica, Vol. 4, Núm. 3, pp. 90-95

2007

  1. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

    Annals of the Rheumatic Diseases, Vol. 66, Núm. 7, pp. 880-885